Target Enabling Packages

Well-validated genetic hits provide a rich source of potential drug targets. Realising this potential requires a deep understanding of the molecular basis of the disease. Narrowing the gap between genetic discovery and new therapeutics relies on the availability of high quality, target-specific research tools.
Here, we provide, free to the community, a selection of Target Enabling Packages (TEPs). TEPs are peer-reviewed tool kits for potential drug targets, produced through collaboration between geneticists, biochemists, medicinal chemists and clinicians. Each TEP includes methods, reagents and knowledge of a protein target, allowing for rapid uptake to a medicinal chemistry campaign.
Each TEP contains:
- Protein production methods
- Biochemical/biophysical assays for activity, affinity
- Structures of the protein, potentially including wild type and disease mutant proteins; full-length or domains; protein-ligand complexes; structures of close homologues
- Initial chemical matter from a fragment or small molecule screen
Additional components of TEPs may be developed on a case-by-case basis, based upon reasonable scientific need, in collaboration with TEP target nominators:
- An antibody or nanobody
- Cell-based assay
- CRISPR knockout
For more information on the TEPs programme, or to pursue a medicinal chemistry collaboration on an available TEP, please contact: teps@cmd.ox.ac.uk
| Gene | Description | Therapeutic Area |
|---|---|---|
| PgDPP11 | Dipeptidyl peptidase 11 | Infectious diseases |
| TREM2 | Triggering receptor expressed on myeloid cells 2 | Neuroscience |
| NSP3 | Nsp3 macrodomain of SARS-CoV-2 | COVID-19 |
| CDKL5 | Cyclin-Dependent Kinase-Like 5 (CDKL5) | Inflammation, Neuropsychiatry |
| SLC14A1 | Urea Transporter B (UT-B;SLC14A1) | Cardiovascular, Metabolic, Neurological Diseases |
| TETRAN | Major facilitator superfamily domain-containg protein 10 (MFSD10), human TETRAN | Inflammation |
| ACVR1 | Activin A receptor, type I (ACVR1) | Inflammation and Oncology |
| NSP15 | SARS-CoV-2 Nidoviral RNA Uridylate‐Specific Endoribonuclease (NSP15) | Infectious diseases |
| NSP13 | SARS-CoV-2 NSP13 | Infectious diseases |
| SLC12A4/SLC12A6 | Potassium/Chloride Co-transporter 1 and 3 (KCC1/KCC3; SLC12A4/SLC12A6) | Sickle cell disease (SCD), Neurological |
| EPB41L3 | EPB41L3 | Neurodegeneration |
| INPP5D | INPP5D (SHIP1) | Neurological Disorders |
| Moesin | MSN (Moesin) | Alzheimer’s disease |
| TNC | Fibrinogen-like globe domain of human Tenascin-C (hFBG-C) | Inflammatory diseases |
| ELOVL7 | Elongation of very long chain fatty acids protein 7 (ELOVL7) | Metabolic diseases |
| DHTKD1 | Dehydrogenase E1 and transketolase domain-containing protein 1 (DHTKD1) | Metabolic diseases |
| DCLRE1C | Artemis (DCLRE1C, SNM1C) | Oncology |
| TBXT | Human T-box transcription factor T (Brachyury) | Cancer |
| KLHL20 | Human Kelch-like protein 20 (KLHL20) | Cancer, Neuropsychiatry |
| STAG1 | Human Stromal Antigen 1 (STAG1) Cohesin Subunit SA-1 | Cancer |
| KEAP1 | Human Kelch-like ECH Associated Protein 1 (KEAP1) | Neuropsychiatry |
| TMEM16K | Human TMEM16K (ANO10) | Neurological Disorders |
| TASK1 | TWIK-Related Acid-Sensitive K+ Channel 1 (TASK1) | Neurological Disorders |
| MTHFR | Methylene-Tetrahydrofolate Reductase (MTHFR) | Metabolic disorders, Cancer |
| ALAS2 | 5'-Aminolevulinate synthase, erythoid-specific (ALAS2) | Metabolic disorders |
| KALRN/RAC1 | Human Kalirin/RAC1 GEF/GTPase Complex | Neurological Disorders |
| PARP14 | Human Poly (ADP-ribose) Polymerase Family Member 14 (PARP14) | Cancer, Inflammation |
| GALT/GALK1 | Human Galactose-1-phosphate uridylyltransferase (GALT), Galactokinase 1 (GALK1) | Metabolic diseases |
| RIPK2 | Human Receptor-Interacting Serine/Threonine-Protein Kinase 2 (RIPK2) | Inflammatory diseases |
| NUDT7 | Human Peroxisomal Coenzyme A Diphosphatase NUDT7 (NUDT7) | Metabolic diseases |
| MLLT1 | Human Mixed- Lineage Leukemia, Translocated to 1 (MLLT1) | Cancer (Acute Myeloid Leukaemia) |
| HCN4 | Hyperpolarization Activated Cyclic Nucleotide Gated Ion Channel 4 (HCN4) | Cardiovascular, Inflammation (homologue of HCN2, an inflammatory pain target), Neuropsychiatry and neuro genetic disorders |
| HAO1 | Human Hydroxyacid Oxidase (HAO1) | Metabolic disorders |
| FAM83B | Human Family With Sequence Similarity 83 Member B (FAM83B) | Cancer |
| LIMK1 | Human LIM Domain Kinase 1 (LIMK1), Kinase Domain | Neuropsychiatry |
| DCLRE1A | Human DNA Cross-Link Repair 1A (DCLRE1A, SNM1A) | Cancer |
| DPAGT1 | Human Dolichyl-Phosphate Alpha-N-Acetyl glucosaminyl transferase (DPAGT1) | Neuropsychiatry and neuro genetic disorders |
| AASS | Human Alpha-Aminoadipic Semialdehyde Synthase (AASS) | Metabolic & Neurological disorders |
| WNK3 | Human With No Lysine Kinase 3 (WNK3) | Metabolic diseases |
| KDM3B | Lysine Demethylase JMJD1B (KDM3B) | Cancer |
| KDM4D | Lysine Demethylase JMJD2D (KDM4D) | Cancer |
| PHIP | Human Pleckstrin Homology Domain Interacting Protein (PHIP) | Cancer |
| RECQL5 | Human RECQL5 helicase | Cancer |
| CDK12 | Human Cyclin-Dependent Kinase 12 (CDK12), Kinase Domain | Oncology |
